Welcome to our dedicated page for Anixa Biosciences SEC filings (Ticker: ANIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anixa Biosciences, Inc. (NASDAQ: ANIX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on cancer treatment and prevention, Anixa uses its filings to report on corporate developments, clinical progress, and communications that may be material to shareholders.
For ANIX, investors can review current reports on Form 8-K, which may include items such as press releases furnished under Regulation FD. For example, the company has filed an 8-K describing the presentation of final data from a Phase 1 clinical trial of its investigational breast cancer vaccine conducted with Cleveland Clinic, and furnished related exhibits such as the press release and presentation abstract.
In addition to 8-Ks, this page is the entry point for other key filing types that are typically important for biotechnology companies, such as annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy statements when filed. These documents can provide detail on Anixa’s ovarian cancer CER-T program, its vaccine portfolio, risk factors, licensing arrangements with institutions like Cleveland Clinic and The Wistar Institute, and other aspects of its business.
Stock Titan enhances these filings with AI-powered summaries that help explain the contents of lengthy reports in plain language. Real-time updates from the SEC’s EDGAR system allow users to see new ANIX filings as they appear, while AI-generated highlights can draw attention to notable sections, such as clinical trial disclosures, intellectual property developments, or changes in corporate structure. Users can also access insider transaction reports on Form 4 when available, alongside the core periodic and current reports.
Anixa Biosciences, Inc. reported that it and The Cleveland Clinic Foundation presented final data from a Phase 1 clinical trial of Anixa’s investigational breast cancer vaccine. The data were shared in a presentation by Justin Johnson, Ph.D., a program manager at Cleveland Clinic and co-inventor of the vaccine technology, and were followed by a company press release. The 8-K primarily alerts investors to the completion and public disclosure of this early-stage clinical trial dataset, with additional details contained in the attached press release and presentation exhibits.
Anixa Biosciences (ANIX) CEO Amit Kumar reported an insider option exercise. On 10/30/2025, he exercised 200,000 stock options at $2.92 per share (code M), adding common shares.
To cover the exercise price and tax withholding, 169,439 shares were withheld and reported as a disposition at $4.06 (code F). Following these transactions, Kumar beneficially owns 610,486 shares directly. The filing notes no open-market share sales in connection with this exercise.
Anixa Biosciences, Inc. (ANIX) filed a shelf registration on Form S-3 that outlines the types of securities it may offer, exhibits that will be incorporated, and selected financial and offering metrics. The prospectus lists potential securities including common stock, preferred stock, purchase contracts, warrants, subscription rights, depositary shares and units. It incorporates multiple recent SEC reports including the annual report for the year ended
Anixa Biosciences (ANIX) reported continued operating losses but states it has sufficient liquidity for over 12 months. The company recorded net losses of $2.3 million for the three months and $8.3 million for the nine months ended July 31, 2025, with losses from operations of $2.4 million and $8.8 million, respectively. Cash, cash equivalents and short-term investments totaled $16,029,000 at July 31, 2025, down from approximately $19,924,000 at October 31, 2024, a reduction of about $3.9 million for the nine months. During the period the company raised approximately $1.924 million, net, from an at-the-market equity offering of 611,686 shares and issued options under its 2018 Share Incentive Plan (1,430,000 granted during the nine months). Stock-based compensation was $829,000 and $2,822,000 for the three- and nine-month periods, respectively. The company continues a 2,000 sq. ft. operating lease for its San Jose office with base rent of approximately $5,000 per month.
Form 4 filing for Anixa Biosciences (ANIX): Company director Lewis H. Titterton, Jr. bought 10,000 common shares on 07/31/2025 at $3.08 per share, an outlay of roughly $30.8 k.
The purchase lifts his direct holding to 953,334 shares. No sales or derivative transactions were disclosed. Because directors are presumed to possess intimate knowledge of corporate prospects, open-market buying is generally interpreted as a positive signal of confidence rather than a routine option exercise.
Form 4 filing overview: On 07/11/2025, Anixa Biosciences (ANIX) Chief Executive Officer Amit Kumar executed an open-market purchase (Code “P”) of 5,000 common shares at $3.15 per share, an aggregate value of roughly $15,750.
Following the transaction, Kumar’s direct ownership increased to 574,925 shares. No derivative securities were reported and the filing was submitted as a single-person report on 07/14/2025.
The purchase represents a ~0.9% increment to Kumar’s previously held position and signals a modest vote of confidence from the company’s most senior executive. However, given the limited dollar amount relative to both his existing stake and the company’s overall share count, the transaction is unlikely to be viewed as a materially game-changing event by the market.